CN103467554A - 药学固体形式 - Google Patents

药学固体形式 Download PDF

Info

Publication number
CN103467554A
CN103467554A CN2013102558234A CN201310255823A CN103467554A CN 103467554 A CN103467554 A CN 103467554A CN 2013102558234 A CN2013102558234 A CN 2013102558234A CN 201310255823 A CN201310255823 A CN 201310255823A CN 103467554 A CN103467554 A CN 103467554A
Authority
CN
China
Prior art keywords
compound
ethynyl
isoallopregnane
etioallocholane
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2013102558234A
Other languages
English (en)
Chinese (zh)
Inventor
斯蒂芬·K·怀特
德怀特·斯蒂克尼
埃林·奥尔松
基斯·R·罗里梅尔
布伦登·S·沃尔夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harbor Therapeutics Inc
Original Assignee
Harbor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harbor Therapeutics Inc filed Critical Harbor Therapeutics Inc
Publication of CN103467554A publication Critical patent/CN103467554A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C07J1/004—Androstane derivatives substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0048—Alkynyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CN2013102558234A 2008-02-05 2009-02-05 药学固体形式 Pending CN103467554A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2647208P 2008-02-05 2008-02-05
US61/026,472 2008-02-05
US9369408P 2008-09-02 2008-09-02
US61/093,694 2008-09-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200980104255XA Division CN101939009B (zh) 2008-02-05 2009-02-05 药学固体形式

Publications (1)

Publication Number Publication Date
CN103467554A true CN103467554A (zh) 2013-12-25

Family

ID=40952461

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2013102558234A Pending CN103467554A (zh) 2008-02-05 2009-02-05 药学固体形式
CN200980104255XA Expired - Fee Related CN101939009B (zh) 2008-02-05 2009-02-05 药学固体形式

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200980104255XA Expired - Fee Related CN101939009B (zh) 2008-02-05 2009-02-05 药学固体形式

Country Status (11)

Country Link
US (4) US8518922B2 (de)
EP (1) EP2249838A4 (de)
JP (1) JP2011511011A (de)
KR (1) KR20100113602A (de)
CN (2) CN103467554A (de)
AU (1) AU2009212314C1 (de)
CA (1) CA2712005C (de)
EA (1) EA018974B9 (de)
HK (1) HK1147695A1 (de)
IL (1) IL207378A0 (de)
WO (1) WO2009100258A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2273994B1 (de) * 2008-04-03 2015-12-02 NeurMedix, Inc. Festphasen-formen eines pharmazeutischen mittels
US20110129423A1 (en) * 2009-11-30 2011-06-02 Frincke James M Anticancer compounds and screening method
WO2011088226A2 (en) 2010-01-13 2011-07-21 Caris Life Sciences Luxembourg Holdings Detection of gastrointestinal disorders
JP5808349B2 (ja) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー セラノーシスのためのバイオマーカー
US9469876B2 (en) 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
AU2011343599A1 (en) * 2010-12-17 2013-05-09 Harbor Biosciences, Inc. Steroid tetrol solid state forms
CN104173353B (zh) * 2013-05-22 2018-08-21 中国医药工业研究总院 不含表面活性剂的固体制剂及其制备方法
WO2015073231A1 (en) * 2013-11-12 2015-05-21 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
CN105434444B (zh) * 2014-09-29 2021-02-05 上海奥奇医药科技有限公司 一种A-失碳-5α雄甾烷化合物的口服制剂
EP3247362A4 (de) 2014-11-17 2018-10-10 Context Biopharma Inc. Onapristonzusammensetzungen mit verlängerter freisetzung und verfahren
AU2016326657B2 (en) 2015-09-25 2019-10-24 Context Biopharma, Inc. Methods of making onapristone intermediates
KR20180113988A (ko) 2015-12-15 2018-10-17 컨텍스트 바이오파마 인코포레이티드 비정질 오나프리스톤 조성물 및 그 제조방법
WO2018102369A1 (en) 2016-11-30 2018-06-07 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
MX2019011649A (es) * 2017-03-30 2019-12-19 Merck Patent Gmbh Forma solida de (s)-[2-cloro-4-fluoro-5-(7-morfolin-4-il-quinazoli n-4-il)fenil]-(6-metoxi-piridazin-3-il)-metanol.
RU2668526C1 (ru) * 2017-08-18 2018-10-01 Федеральное государственное бюджетное учреждение "Информационно-методический центр по экспертизе, учету и анализу обращения средств медицинского применения" Федеральной службы по надзору в сфере здравоохранения Способ идентификации и последующего количественного определения основных компонентов в инъекционных лекарственных средствах
CA3121170A1 (en) 2018-11-30 2020-06-04 Caris Mpi, Inc. Next-generation molecular profiling
CN111773388B (zh) * 2019-04-04 2023-07-18 上海奥奇医药科技有限公司 A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用
WO2021112918A1 (en) 2019-12-02 2021-06-10 Caris Mpi, Inc. Pan-cancer platinum response predictor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567830A (en) * 1994-02-14 1996-10-22 Cocensys, Inc. Process for synthesis of acetylenic carbinols
US20070129548A1 (en) * 2005-12-07 2007-06-07 Lushi Tan Polymorphs of an androgen receptor modulator
US20080021006A1 (en) * 1999-09-30 2008-01-24 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical Compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE681869C (de) * 1935-11-22 1939-10-03 Schering Ag Verfahren zur Darstellung von tertiaeren Alkoholen der Cyclopentanopolyhydrophenanthrenreihe
CH202847A (de) * 1937-06-26 1939-02-15 Chem Ind Basel Verfahren zur Darstellung von Acetylen-Derivaten der Cyclopentanopolyhydrophenanthren-Reihe.
DK0614456T3 (da) * 1992-08-28 1999-12-06 Bone Care Int Inc 1alfa,24(S)-dihydroxy-vitamin D2, dets fremstilling og anvendelse
CZ294413B6 (cs) 1996-03-29 2004-12-15 Duphar International Research B. V. Piperazinová nebo piperidinová sloučenina, způsob její přípravy, farmaceutický prostředek tuto sloučeninu obsahující a použití této sloučeniny pro přípravu farmaceutického přípravku
ZA986614B (en) * 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
US7045513B1 (en) * 1999-03-18 2006-05-16 Genelabs Technologies, Inc. DHEA composition and method
US6777399B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
KR100899032B1 (ko) * 2000-12-14 2009-05-21 오르토-맥네일 파마슈티칼, 인코퍼레이티드 비결정형의 안정화제를 포함하는 스테로이드 호르몬 제품
AR034206A1 (es) 2001-02-16 2004-02-04 Solvay Pharm Bv Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos
DE10314610A1 (de) * 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
US7540016B2 (en) * 2004-07-21 2009-05-26 Beachhead Solutions, Inc. System and method for lost data destruction of electronic data stored on a portable electronic device which communicates with servers that are inside of and outside of a firewall
US7964604B2 (en) * 2005-02-18 2011-06-21 Solvay Pharmaceuticals B.V. Bifeprunox mesylate maintenance dose compositions and methods for using the same
TWI305979B (en) * 2006-03-24 2009-02-01 Hon Hai Prec Ind Co Ltd Wireless transceiving system
EP2486924B1 (de) * 2006-04-22 2018-12-26 Neurmedix, Inc. Wirkstoffe und deren Anwendungen
DE102007054497B3 (de) * 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567830A (en) * 1994-02-14 1996-10-22 Cocensys, Inc. Process for synthesis of acetylenic carbinols
US20080021006A1 (en) * 1999-09-30 2008-01-24 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical Compositions
US20070129548A1 (en) * 2005-12-07 2007-06-07 Lushi Tan Polymorphs of an androgen receptor modulator

Also Published As

Publication number Publication date
WO2009100258A1 (en) 2009-08-13
AU2009212314C1 (en) 2014-05-08
US20090291932A1 (en) 2009-11-26
AU2009212314A1 (en) 2009-08-13
US8518922B2 (en) 2013-08-27
US20130345455A1 (en) 2013-12-26
US9314471B2 (en) 2016-04-19
US20130338125A1 (en) 2013-12-19
JP2011511011A (ja) 2011-04-07
EP2249838A1 (de) 2010-11-17
KR20100113602A (ko) 2010-10-21
CA2712005A1 (en) 2009-08-13
EA201070713A1 (ru) 2011-08-30
EA018974B1 (ru) 2013-12-30
HK1147695A1 (en) 2011-08-19
EA018974B9 (ru) 2014-04-30
EP2249838A4 (de) 2012-05-02
US20130345184A1 (en) 2013-12-26
AU2009212314B2 (en) 2013-11-21
CN101939009A (zh) 2011-01-05
IL207378A0 (en) 2010-12-30
CN101939009B (zh) 2013-07-17
CA2712005C (en) 2014-04-15

Similar Documents

Publication Publication Date Title
CN101939009B (zh) 药学固体形式
Burton et al. NCI comparative oncology program testing of non-camptothecin indenoisoquinoline topoisomerase I inhibitors in naturally occurring canine lymphoma
CN105324381A (zh) 有关1-乙基-7-(2-甲基-6-(1H-1,2,4-三唑-3-基)吡啶-3-基)-3,4-二氢吡嗪并[2,3-b]吡嗪-2(1H)-酮的药物制剂、程序、固体形式和使用方法
US20060234992A1 (en) DHEA composition and method
Yap et al. First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies
JP2006505564A (ja) Ｓａｒｍによる高齢男性のアンドロゲン減少に関連する病気の治療
AU779138B2 (en) DHEA composition and method
WO2023212071A1 (en) Combination and the use thereof
CA2945960C (en) Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
JP2017511367A (ja) １−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン及び共形成物を含む固体形態、その組成物及び使用方法
WO2016101868A1 (zh) 萘普替尼对甲苯磺酸盐的β晶型及制备方法和含有其的药物组合物
CN110563644A (zh) 一种仑伐替尼甲磺酸盐的新晶型
US10385072B2 (en) Gold(III) complexes as anticancer agents and a method of treating cancer
WO2023275248A1 (en) A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product
WO2023209611A1 (en) Methods of treating cancer with a b-raf inhibitor, in particular lifirafenib
WO2024039691A1 (en) N-(1-((r)-1-acryloylazepan-3-yl)-7-chloro-6-(((r)-tetrahydrofuran-3-yl)oxy)-1h-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (nx-019) for use in the treatment of egfr mutant cancer
Heist DF/HCC Protocol#:[16-019] TITLE: A Phase 2 Study of INC280 in NSCLC patients with MET exon 14 alterations or MET amplification who have received prior MET inhibitor. Coordinating Center: Massachusetts General Hospital* Principal Investigator (PI): Rebecca S. Heist MD MPH
CN108025009A (zh) 喹喔啉基-哌嗪酰胺的使用方法
Kogermann et al. Preparation and Stabilization of Amorphous Piroxicam Using Co-milling Approach

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20131225